12:00 AM
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AB0024: Phase I data

In a dose-escalation Phase I trial in 3 patients, 1 mg/kg AB0024 every 2 weeks was well tolerated. An additional 3 patients are being enrolled at...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >